Cambridge Investment Research Advisors Inc. Buys 9,744 Shares of Danaher Co. (NYSE:DHR)

Cambridge Investment Research Advisors Inc. increased its position in Danaher Co. (NYSE:DHR) by 20.3% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 57,659 shares of the conglomerate’s stock after purchasing an additional 9,744 shares during the period. Cambridge Investment Research Advisors Inc.’s holdings in Danaher were worth $13,339,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of DHR. Banco Santander S.A. purchased a new stake in shares of Danaher during the third quarter valued at approximately $683,000. Cary Street Partners Investment Advisory LLC raised its stake in shares of Danaher by 20.2% in the fourth quarter. Cary Street Partners Investment Advisory LLC now owns 9,128 shares of the conglomerate’s stock worth $2,112,000 after purchasing an additional 1,533 shares during the last quarter. First Citizens Bank & Trust Co. raised its stake in shares of Danaher by 0.6% in the fourth quarter. First Citizens Bank & Trust Co. now owns 26,611 shares of the conglomerate’s stock worth $6,156,000 after purchasing an additional 149 shares during the last quarter. Cercano Management LLC lifted its holdings in shares of Danaher by 11.4% during the fourth quarter. Cercano Management LLC now owns 202,569 shares of the conglomerate’s stock valued at $46,862,000 after purchasing an additional 20,715 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC boosted its position in shares of Danaher by 48.1% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 296,996 shares of the conglomerate’s stock valued at $68,707,000 after buying an additional 96,395 shares during the last quarter. 79.05% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Danaher

In other news, Director Alan G. Spoon sold 708 shares of the business’s stock in a transaction on Thursday, May 2nd. The shares were sold at an average price of $243.58, for a total value of $172,454.64. Following the transaction, the director now owns 116,202 shares of the company’s stock, valued at $28,304,483.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In related news, CEO Rainer Blair sold 9,005 shares of the stock in a transaction that occurred on Thursday, May 16th. The stock was sold at an average price of $265.00, for a total transaction of $2,386,325.00. Following the completion of the transaction, the chief executive officer now directly owns 106,990 shares of the company’s stock, valued at $28,352,350. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Alan G. Spoon sold 708 shares of Danaher stock in a transaction that occurred on Thursday, May 2nd. The stock was sold at an average price of $243.58, for a total value of $172,454.64. Following the completion of the sale, the director now directly owns 116,202 shares in the company, valued at approximately $28,304,483.16. The disclosure for this sale can be found here. Insiders sold a total of 172,540 shares of company stock valued at $43,523,481 in the last three months. 11.10% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

DHR has been the topic of a number of recent analyst reports. TD Cowen raised their price target on shares of Danaher from $280.00 to $290.00 and gave the company a “buy” rating in a report on Wednesday, April 24th. Raymond James lifted their target price on shares of Danaher from $240.00 to $270.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 31st. HSBC raised Danaher from a “hold” rating to a “buy” rating and increased their price target for the company from $250.00 to $280.00 in a report on Wednesday, April 17th. Bank of America lifted their price objective on Danaher from $258.00 to $270.00 and gave the stock a “neutral” rating in a report on Wednesday, April 24th. Finally, Barclays raised their target price on Danaher from $260.00 to $270.00 and gave the stock an “equal weight” rating in a research report on Wednesday, April 24th. Six research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $267.31.

Danaher Stock Performance

Shares of NYSE DHR opened at $262.78 on Friday. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.85 and a quick ratio of 1.51. Danaher Co. has a 1 year low of $182.09 and a 1 year high of $268.98. The firm has a fifty day moving average price of $249.96 and a 200-day moving average price of $238.95. The stock has a market cap of $194.64 billion, a PE ratio of 44.54, a price-to-earnings-growth ratio of 4.02 and a beta of 0.83.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.72 by $0.20. Danaher had a return on equity of 11.43% and a net margin of 16.78%. The business had revenue of $5.80 billion during the quarter, compared to analyst estimates of $5.62 billion. During the same quarter in the prior year, the business posted $2.36 EPS. Danaher’s revenue for the quarter was down 2.6% compared to the same quarter last year. Equities analysts anticipate that Danaher Co. will post 7.63 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, July 26th. Shareholders of record on Friday, June 28th will be paid a $0.27 dividend. The ex-dividend date of this dividend is Friday, June 28th. This represents a $1.08 annualized dividend and a yield of 0.41%. Danaher’s payout ratio is 18.31%.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.